More on Multiple Myeloma From ASCO 2023 Focus on Bispecific ...

The overall response rate to the combination was 86.6% across all dose levels and 96.3% in patients treated with the recommended phase II ...

Bispecific antibodies and dual-targeting CAR-T cells for multiple ...

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting · Jiangxue Hou · Yufu ...

Multiple Myeloma - The ASCO Post

In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple ...

Expert Insights on Important Updates in Multiple Myeloma With Marc ...

These bispecific antibodies are practice changing. They are very impactful at treating heavily pretreated patients who are resistant to any ...

2023 ASCO and EHA: Bispecifics, CAR T, and More!

In June 2023, a large number of myeloma research abstracts were presented by pre-eminent experts at the annual congresses of the American ...

Bispecific Antibody Use in Patients With Lymphoma and Multiple ...

or refractory multiple myeloma (RRMM) after four or more prior lines of therapy are elranatamab, teclistamab, and talquetamab on the basis ...

Bi-Specific Myeloma Study LINKER-MM1 Results - HealthTree

ASCO 2023: A New BCMA-Targeting Bi-specific Antibody, Linvoseltamab · 252 myeloma patients have enrolled in this trial. 104 patients were ...

ASCO: Bispecific Antibodies for Multiple Myeloma - Patient Power

Is patient excitement about bispecific antibodies warranted? From the 2023 ASCO annual meeting, Hans Lee, MD, discusses the advantages of ...

T cell Redirecting Bispecific Antibodies for Multiple Myeloma

However, CAR-T cell therapy has logistical limitations and there is a need for immunotherapies that are readily available, safe, and effective in RRMM.

Updates in Multiple Myeloma from ASCO 2023 for Healthcare ...

Bispecific Antibody Combinations ... A combination of two novel bsAbs, teclistamab and talquetamab, has shown promise with respect to both response rate and ...

Efficacy and safety of bispecific antibodies therapy for relapsed or ...

There are several BsAb formats, most of BsAbs used in MM target B-cell maturation antigen (BCMA), whereas others target non-BCMA antigens, ...

Dr Richter on the Current State of Bispecific Antibodies in Multiple ...

The prominence of bispecific antibodies is underscored by the fact that approximately 80% of patients with myeloma in the United States are ...

ASH 2023: Raising the BCMA Standard in Multiple Myeloma

The overall response rate for talquetamab was 73% but lower with a past bispecific antibody. It has side effects like dysgeusia which is altered ...

Management of Adverse Effects in Patients With Multiple Myeloma ...

For patients with RRMM, BsAbs represent a new treatment option, with several now approved by the US Food and Drug Administration (FDA) and more ...

Sequencing Immunotherapy for Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies have transformed the management of relapsed/refractory multiple ...

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for ...

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) ...

New Bispecific Antibody Demonstrates Clinical Activity in Patients ...

– Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting ...

Disparities in access to CAR-T and BsAb therapy for multiple myeloma

ASCO 2023 | Disparities in access to CAR-T and BsAb therapy for multiple myeloma · More from Surbhi Sidana · Related Videos.

Teclistamab Reviewed as Potential Treatment Option in Relapsed ...

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

An Intense and Exciting ASH 2023| Int'l Myeloma Foundation

A considerable number of abstracts also deal with immune biology and the efficacy and toxicities of both CAR T cell products and bispecific plus ...